Companies / BMY vs VTRS
BMY vs VTRS: Bristol Myers Squibb and Viatris
Bristol Myers Squibb (BMY) reported $48.2B in revenue against a 14.6% net margin, while Viatris (VTRS) reported $14.3B at a -24.6% net margin, most recently.
| Metric | BMY | VTRS |
|---|---|---|
| Revenue | $48.2B | $14.3B |
| Net Income | $7.1B | $-3.5B |
| Gross Margin | 71.1% | 35.1% |
| Operating Margin | 19.4% | -18.6% |
| EPS (Diluted) | $3.46 | $-3.00 |
| Free Cash Flow | $12.8B | $1.9B |
| Total Debt | $47.1B | $14.4B |
| P/E Ratio | 15.6× | n/m |
| P/B Ratio | n/m | n/m |
| Stock Price | $63.16 | $19.00 |
Free: last 5 years
| Fiscal year | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| BMY Revenue | ••••• | ••••• | ••••• | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| VTRS Revenue | ••••• | ••••• | ••••• | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |